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Background: Recently, we and others proposed plasticity-related gene 3 (PRG3) as a novel molecule in
neuritogenesis based on PRG3 overexpression experiments in neuronal and non-neuronal cell lines. However, direct
information on PRG3 effects in neuronal development and, in particular, its putative spatio-temporal distribution
and conditions of action, is sparse.
Results: We demonstrate here that PRG3 induces filopodia formation in HEK293 cells depending on its
N-glycosylation status. The PRG3 protein was strongly expressed during mouse brain development in vivo from
embryonic day 16 to postnatal day 5 (E16 – P5). From P5 on, expression declined. Furthermore, in early, not yet
polarized hippocampal cultured neurons, PRG3 was expressed along the neurite shaft. Knock-down of PRG3 in
these neurons led to a decreased number of neurites. This phenotype is rescued by expression of an
shRNA-resistant PRG3 construct in PRG3 knock-down neurons. After polarization, endogenous PRG3 expression
shifted mainly to axons, specifically to the plasma membrane along the neurite shaft. These PRG3 pattern changes
appeared temporally and spatially related to ongoing synaptogenesis. Therefore we tested (i) whether dendritic
PRG3 re-enhancement influences synaptic currents and (ii) whether synaptic inputs contribute to the PRG3 shift.
Our results rendered both scenarios unlikely: (i) PRG3 over-expression had no influence on miniature excitatory
postsynaptic currents (mEPSC) and (ii) blocking of incoming signals did not alter PRG3 distribution dynamics. In
addition, PRG3 levels did not interfere with intrinsic neuronal properties.
Conclusion: Taken together, our data indicate that endogenous PRG3 promotes neurite shaft protrusion and
therefore contributes to regulating filopodia formation in immature neurons. PRG3 expression in more mature
neurons, however, is predominantly localized in the axon. Changes in PRG3 levels did not influence intrinsic or
synaptic neuronal properties.
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Developing neurons extend long neurites to create a
complex network. Key structures in the elongation of
neurites are a highly motile growth cone and a stable
neurite shaft, the latter generated by the suppression of
protrusive activity. Neurite elongation and branching are
governed by coordinated rearrangements of the cytoskel-
etal dynamics of actin and microtubules [1-3]. The actin
cytoskeleton provides protrusive and contractile forces
and microtubules form a polarized network allowing or-
ganelle and protein movement throughout the cell.* Correspondence: anja.braeuer@charite.de
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reproduction in any medium, provided the orNeurite protrusion requires a protrusive force to push
the plasma membrane forward, as well as an addition of
membrane materials. This includes microtubule frag-
mentation and local accumulation of F-actin for the for-
mation of filopodia and lamellipodia and subsequent
neurite branching, also called sprouting [4]. In addition,
protein glycosylation has been proposed to play a cru-
cial role in the regulation of neurite elongation and
branching [5,6]: proteins that have been shown to regu-
late neurite outgrowth are regulated by N-linked oligo-
saccharides in folding and activity [7]. Many proteins
involved in the coordination between microtubules and
actin have been identified [8,9]. Among these, calpain,
which is localized along the neurite shaft, prevents
branching through the proteolysis of cortactin [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vates the actin-related protein 2/actin-related protein 3
complex (Arp2/3) to initiate filopodia formation. This sig-
naling pathway is extensively studied and apparently not
only involved in neurite extension [11]. The stabilisation
or destabilisation of the cytoskeleton by intracellular sig-
naling cascades is, in turn, controlled by extracellular cues.
Among others, phospholipids such as lysophosphatidic
acid (LPA) and sphingosin-1-phosphate (S1P) mediate cell
motility, growth, proliferation and survival [12-15]. Modu-
lation of phospholipid signaling occurs by members of the
lipid phosphatase/phosphotransferase family (LPT, also
known as PAP2) [16]. One LPT subgroup consists of the
vertebrate-specific plasticity-related genes (PRGs, also
termed lipid-phosphatase-related proteins, LPRs) [17].
One of the five known PRGs is PRG3 (LPR1), an inte-
gral membrane protein with six predicted transmembrane
helices linked by intra- and extracellular loops [16,18].
Previous analyses showed that PRG3 mRNA is expressed
as early as embryonic day 14 in cerebral cortex and hippo-
campus formation [18,19], suggesting a role in neuronal
differentiation. Cortical PRG3 showed a gradient of expres-
sion with a higher level of expression in the dorsal cortex
in comparison to the lateral cortex [19]. The mRNA level
decreased to basal expression in adulthood [18]. Functional
tests of PRG3 suggested a role during neurite outgrowth:
PRG3 overexpression induced the formation of actin-rich,
dynamic filopodia in several cell lines such as N1E-115,
HeLa, and COS-7 cells [18,20]. Interestingly, this induction
was not mediated by cdc42 or Rif, a Rho-family GTPase,
and was independent of the Arp2/3 complex [20]. The
neurite outgrowth was also not directly linked to phosphat-
ase activity against any of the well-characterized LPT sub-
strates, because no enzymatic activity for PRG3 was shown
[18,20]. This study was designed to transfer findings on
PRG3 actions to a neuronal, physiologically relevant devel-
opmental context and clarify the functional importance of
endogenous PRG3. Our results indicate that i) PRG3 in
immature neurons is located in all neurite shafts, where it
determines neurite protrusions; ii) PRG3 expression in
more mature neurons is predominantly axonal; iii) PRG3
expression patterns are not influenced by and do not influ-
ence synaptic currents; and iv) glycosylation of PRG3 is a
prerequisite for membrane insertion.Methods
Animals
Pregnant, postnatal and adult C57BL/6 mice obtained from
our central animal facility were kept under standard la-
boratory conditions (12 hour light/dark cycle; 55% +/-15%
humidity; 24°C +/-2°room temperature and water ad
libitum, enriched and grouped) in accordance with
German and European guidelines (2010/63/EU) for the useof laboratory animals. Approval of experiments was
obtained from the local ethics body of Berlin (LAGeSO:
T0108/11).Constructs
For overexpression of rPRG3 and mPRG3 (GenBank
Accession no. AY299399, rat PRG3; NM_178756, mouse
PRG3) in HEK293 cells, the following expression plas-
mids were used: pGFP-N1-rPRG3, pGFP-N1-mPRG3
and p3×FLAG-CMV-7.1-rPRG3. For Western blot ana-
lyses we used the following expression plasmids:
mPRG1-eGFP, rPRG2-eGFP, mPRG4-eGFP, and rPRG5-
eGFP. The sequence of the mature rPRG3 protein was
subcloned from pGFP-N1-rPRG3 into p3×FLAG-
CMV7.1 (Sigma-Aldrich, St. Louis, MO, USA) via Hind
III and Sal I. The fragment was amplified using the
following primers: 5´-AAG CTT ATG GCT GTA GAG
AAC AAC-3´ and 5´-GTC GAC TCA GGT GAC TTC
GGT CAT-3´ (Metabion, Martinsried, Germany). mPRG3
was amplified using the following primers: 5´-CTC
GAG ATG GCT GTA GAA AAC AAC AC-3´ and 5´-
GGT ACC CAG ACT TCG GTC ATG-3´. Ligation
into pGFP-N1 (Clontech Laboratories Inc, Mountain
View, CA, USA) was performed via XhoI and KpnI.
For knock-down of endogenous PRG3 (shPRG3) the
following oligonucleotides were annealed and ligated
into pSuper-eGFP (Oligoengine, Seattle, WA, USA):
5´-GAT CCC CCT TCA GAG GAA CCC AAG GCT
TCA AGA GAG CCT TGG GTT CCT CTG AAG TTT
TTG GAA A-3´ and 5´-AGC TTT TCC AAA AAC
TTC AGA GGA ACC CAA GGC TCT CTT GAA GCC
TTG GGT TCC TCT GAA GGG G-3´. As a control we
used a shRNA target sequence against firefly luciferase.
The following oligonucleotides were annealed and li-
gated into pSuper-GFP: 5´-GAT CCC CCG TAC GCG
GAA TAC TTC GAT TCA AGA GAT CGA AGT ATT
CCG CGT ACG TTT TTG GAA A-3´ and 5´-AGC
TTT TCC AAA AAC GTA CGC GGA ATA CTT CGA
TCT CTT GAA TCG AAG TAT TCC GCG TAC GGG
G-3´. For the PRG3 shRNA rescue plasmid, four silent
mutations were introduced into the region targeted by
the shPRG3. Site-directed mutagenesis was carried out
with QuikChange site-directed matagenesis kit (Strata-
gene, CA, USA). Forward primer 5´ –G GGA ATG
TGT GTG GTT CAT AAC TTT AGG GGC ACA
CAA GGC TCT CCT TCC AAA CC– 3´ and the re-
verse primer 5’ –GG TTT GGA AGG AGA GCC TTG
TGT GCC CCT AAA GTT ATG AAC CAC ACA CAT
TCC C- 3´ (mutated amino acids underlined) (Metabion,
Martinsried, Germany) were chose. The mutated full-
length mPRG3 gene was subcloned into the pDsRed2-N1
via XhoI and KpnI. Sequences of all the cDNAs were
conformed by sequencing.
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Two polyclonal rabbit antibodies recognizing different
sequences of PRG3 protein were generated. One was
targeted to a sequence on the first extracellular loop
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Figure 1 Specific binding of PRG3 antibodies to intra- and extracellul
rPRG3 with its predicted orientation in the plasma membrane. Transmemb
N-terminal regions are located on the intracellular side. The putative N-glyc
generate the PRG3 antibodies in blue, and loci that differ between PRG3 o
PRG3 antibodies revealed that anti-PRG3 53 (B) and anti-PRG3 296 (C) show
rPRG3 or endogenous PRG3 from mouse brain were probed with the antib
antibody (Western blot) showed a double band with either anti-PRG3 53 o
antibody with BSA yielded the same result (B and C, middle), whereas a sim
immunoreactivity (B and C, right). (D) Specificity analysis of the two anti-PR
members. Fusion proteins of several PRG family members with eGFP (PRG1
analyses. Both used PRG3 antibodies (anti-PRG3 296 and 53) detected proton the intracellularly located C-terminus (aa 296 – 309;
anti-PRG3 296). The sequences used to generate both
antibodies were identical between rat and mouse PRG3
and are highlighted in blue in Figure 1A. The pep-
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ar domains. (A) Schematic depiction of the amino acid sequence of
rane-spanning domains (grey) are labeled TM1-TM6 and the C- and
osylation site at asparagine 163 is indicated in red, sites used to
f mouse and rat in green. (B and C) Specificity analysis of the two anti-
similar immunoreactivity. HEK293 cell lysates overexpressing GFP-
odies under different conditions. Membranes probed with the native
r anti-PRG3 296 (B and C, left). A two-hour preincubation of the
ilar preincubation with the corresponding peptide abolished
G3 antibodies revealed no cross reactivity to other PRG family
, PRG2, PRG3, PRG4, and PRG5) were used in the Western blot
ein exclusively in the PRG3 lane as a double band.
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PRG3 53 and 296 were synthesized by BioGenes (Berlin,
Germany). The N-terminal cysteine residue was inclu-
ded for conjugation of the peptide to a carrier protein.
Immunization and antibody production were perfor-
med by BioGenes. The antibodies were subsequently
affinity-purified against the corresponding peptide with
HiTrap NHS-activated HP columns (GE Healthcare,
Buckinghamshire, UK) according to the manual. The
antibody was dialyzed against PBS and stored at −20°C.
The specificity of the antibodies was tested by immuno-
blot analysis. Here the antibody was preincubated with
the corresponding peptide or BSA for control, for 2
hours at room temperature (RT) before adding the anti-
body to the membrane.
Cell line transfection
HEK293 cells (human embryonic kidney) were routinely
maintained at 37°C with 5% CO2 in DMEM (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal calf
serum (Pan Biotech, Aidenbach, Germany), 100 U/ml
penicillin and 100 μg/ml streptomycin (Pan Biotech).
HEK293 cells were plated in 6- or 12-well plates with a
density of 20,000 cells/cm2 and transfected the next day
with calcium phosphate precipitation: 4 μg DNA, 67.5 μl
sterile water, 7.5 μl calcium chloride and 67.5 μl 2 ×
Hepes-buffered saline were mixed and either the whole
amount added to one well for the 6-well plates or di-
vided into two wells for the 12-well plates. One day after
transfection the cells were used for further analyses.
Primary mouse hippocampal neuron, astrocyte and
microglial cultures
Hippocampal neurons were isolated from C57BL/6 mouse
embryos at embryonic day 18. Hippocampi from several
embryos were collected and washed twice in ice-cold HBSS
(Invitrogen). The tissue was incubated in 4 ml HBSS
and 400 μl trypsin (Invitrogen) for 15 minutes at 37°C, re-
suspended in plating medium (MEM supplemented with
10% horse serum, (both Invitrogen) 0.6% glucose, 100 U/ml
penicillin and 100 μg/ml streptomycin). After dissociation,
the neurons were plated in plating medium onto poly-L-ly-
sine (Sigma-Aldrich) coated cover slips into 12-well plates
or dishes with a cell density of 10,000 – 20,000 cells/cm2 or
for a low-densitiy cell culture 5,000 – 10,000 cells/cm2.
Three hours after plating, cells were washed twice with
phosphate-buffered saline (1 × PBS) and incubated in
Neurobasal A medium (Invitrogen) supplemented with 2%
B27 (Invitrogen), 0.5 mM glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin at 37°C and 5% CO2. For electro-
physiological experiments neurons were plated with a dens-
ity of 39,500 cells/cm2 and cultured in the absence of
antibiotics. To block synaptic activity the medium was
supplemented with 20 μM CNQX to block AMPA/kainatereceptors, 100 μM DAPV to block NMDA receptors, and 4
μM gabazine to block GABAA receptors. Medium was
changed every second day. The treatment started from DIV
4 and lasted until DIV 14.
Astrocytes and microglia were prepared as previously
described [21]. Briefly, mouse cortex (P1-3) was isolated
and carefully homogenized. Digestion was performed by
10 minutes trypsin incubation. Dissociated glial cells
were plated on poly-L-lysine-coated dishes and incu-
bated at 37°C with 5% CO2. After two days the medium
was refreshed and the cells were incubated until most of
the microglial cells had detached from the astrocytes.
The cells were shaken for two hours at 37°C and the
remaining free-floating microglia were removed.
Preparation of total protein lysates and recombinant
proteins
HEK293 cells were washed with ice-cold PBS, lysed in a
detergent-containing lysis buffer (50 mM Tris pH 7.4,
150 mM NaCl, 1% NP-40, 25 mM MgCl2, 10% Glycerol)
containing protease inhibitors (Sigma-Aldrich), and son-
icated 3 × 3 seconds. Subsequently, the lysates were
centrifuged for 10 minutes at 14,000 × g and 4°C.
Mouse primary cells or organs were lysed in non-
detergent-containing lysis buffer (20 mM Tris pH 7.5, 5
mM EDTA, 1 mM EGTA, 25 mM sucrose) with prote-
ase inhibitors. After sonication, the lysates from primary
cells or organs were incubated on ice for 30 minutes and
centrifuged for 5 minutes at 5000 × g and 4°C. Protein
concentration of the supernatant was determined by a
BCA Protein Assay Kit (Thermo Scientific, Rockford, IL,
USA). To obtain recombinant protein, PRG1-eGFP,
PRG2-eGFP, PRG3-eGFP and PRG5-eGFP were purified
from transfected HEK-293 cells using the μMACS
Epitope Tagged Protein Isolation Kit (Miltenyi Biotech,
Bergisch Gladbach, Germany), as recommended by the
manufacturer.
Immunoblotting
Protein extracts from cells or tissues were subjected to
12% SDS-PAGE under reducing conditions and then
blotted to a nitrocellulose membrane (Whatman, Dassel,
Germany) by semi-dry protein transfer. Blots were
blocked for 1 hour at RT in 10% non-fat dry milk diluted
in PBS and then incubated overnight at 4°C with a 1:500
dilution of anti-PRG3 53 or 296, 1:1000 dilution of anti-
FLAG (Sigma-Aldrich), 1:1000 dilution of anti-GFP
(Clontech), 1:10000 dilution of anti-β-actin (Sigma-
Aldrich), 1:5000 dilution of anti-GFAP (Millipore,
Temecula , CA, USA) or 1:2500 dilution of anti-tuj1
(Covance, Berkeley, CA, USA). After three washes in 1 ×
PBS, the membranes were incubated with a 1:5000 dilu-
tion of an anti-mouse or anti-rabbit horseradish
peroxidase-labeled antibody (GE Healthcare) for 2 hours
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bated with a 1:2000 dilution of anti-Iba1 (Wako Pure
Chemicals Industries, Osaka, Japan) in 5% non-fat dry
milk, for 1 hour at RT. After three washes in PBS the
membranes were incubated with horseradish peroxidase-
labeled anti-rabbit secondary antibody 1:5000 diluted in 1 ×
PBS containing 5% non-fat dry milk for 45 minutes at RT.
Immunoreactive bands were detected using ECL Western
blotting detection reagents (GE Healthcare).The inten-
sity of the Western blots bands was measured by using
the MetaMorph Software, Version 6.2r6. The gray inten-
sity of the control band was set to 100%. All other bands
were calculated to the control. Beta-actin was used for
normalization.
Deglycosylation of PRG3
For detection of potential N-glycosylation, mouse brain
or HEK293 total protein lysates were treated with
peptide-N-glycosidase F (PNGase F, Roche Applied Sci-
ence, Mannheim, Germany) as recommended by the
manufacturer. Controls of mouse brain or HEK293 pro-
tein lysates were treated using the same process but
without PNGase F.
Point mutation of PRG3
Point mutation of the AS 163 of PRG3 from asparagine to
glutamine within the expression plasmid p3×FLAG-
CMV7.1-rPRG3 was performed with the QuikChange II
Site-Directed Mutagenesis Kit (Stratagene, Cedar Creek,
TX, USA) using the following primers: for 5´-CTGACA
GTGTGCCAGCCACAATATACCAGTACAGACTGC-3´
and rev 5´-GCAGTCTGTACTGGTATATTGTGGCTGG
CACACTGTCAG-3´ (Metabion) as recommended by the
manufacturer.
Electrophysiology
Hippocampal neurons were transfected at 11 or 12 days
in vitro (DIV) using Effectene (Qiagen GmbH, Hilden,
Germany) according to the manufacturer’s specifications.
One to three days post transfection neurons were placed
in a bathing solution consisting of (in mM): 124 NaCl,
4 KCl, 3 CaCl2, 2 MgCl2, 25 HEPES, 10 glucose; pH
adjusted to 7.3 with NaOH. An inverted microscope
(IM35, Zeiss AG, Oberkochen, Germany) equipped with
phase contrast, a 25× objective and a 50 W mercury
lamp was used to visualize neurons. Pipettes were filled
with an intracellular solution comprising 120 K-gluconate,
10 KCl, 10 Na-phosphocreatine, 1 MgCl2, 1 CaCl2, 11
EGTA, 10 HEPES, 2 Mg2+ ATP and 0.3 GTP (in mM); pH
set to 7.2 with KOH. Intracellular solution was stored on
ice. Miniature excitatory postsynaptic currents (mEPSCs)
were recorded at a holding potential of −70 mV and in a
bath solution containing 0.5 μM TTX (Tocris, Bristol,
UK) and 10 μM bicuculline (Tocris). Experiments wereperformed at RT (21 – 24°C) with an EPC-10 patch clamp
amplifier (HEKA, Lambrecht, Germany) controlled by
Pulse (v8.78, HEKA) software. All recordings were filtered
with a 2.9 kHz Bessel-filter and sampled with a minimum
frequency of 6.25 kHz. Analysis of intrinsic neuronal
properties was performed using PulseFit (HEKA) and Ori-
gin 7 (Originlab Corp, Northampton, MA, USA). mEPSCs
were analyzed with WinEDR and WinWCP (University of
Strathclyde electrophysiology software; author John
Dempster, UK). The automatic detection parameters were
set to a threshold of 8 pA and a dead time of 15 ms. Al-
though the threshold was about two times the noise level,
false–positive events were detected and detection failures
occurred, therefore a visual identification of events was
performed. The amplitude of mEPSCs was calculated
from the averaged baseline before the event to the 5 point
averaged peak of the event. Data were compiled and
presented using Origin. Statistical analysis was performed
in Origin and StatView (Abacus Concepts Inc, CA, USA).
ANOVA was used for multiple comparisons, student’s t-
test for two normal distributed data sets and Mann–Whit-
ney U test for two non-normal distributed data sets. Sig-
nificance level was set to p < 0.05 (*). Data from individual
experiments are presented as box plots with boxes show-
ing the 25th and 75th percentile, as well as the maximum
and minimum. A line crossing the box and individual data
points indicates the mean.Immunostaining of cultured cell lines and primary
neurons
Primary hippocampal mouse neurons and transfected
neurons at 1, 4 and 14 DIV or transfected HEK293 cells
were fixed in ice-cold 4% paraformaldehyde with 15%
sucrose in PBS for 20 minutes at RT and washed three
times with PBS. Permeabilization was performed by
adding 0.1% Triton X-100, 0.1% sodium citrate in PBS
for 3 minutes at 4°C. After washing the cells three times
they were blocked with 10% fetal calf serum (FCS) for 1
hour at RT. Cells were then incubated with primary anti-
body in 10% FCS in PBS overnight at RT in the follow-
ing dilutions: 1:200 anti-PRG3 296, 1:200 anti-tau1
(Chemicon, Temecula, CA, USA), 1:1500 anti-β-actin,
1:1500 anti-α-tubulin, 1:1000 anti-MAP2, anti-Tuj1 or
1:500 anti-FLAG (all Sigma-Aldrich), 1:5000 anti-GFP
and anti-Na+/K+-ATPase (Abcam). After three washes
with PBS, Alexa Fluor-conjugated secondary antibodies
(Invitrogen), diluted 1:1500 in PBS containing 10% FCS,
were added for 90 minutes at RT. Finally, cells were
washed three times and mounted with Immu-mount
(Thermo Scientific). Confocal images were acquired with
an upright laser microscope (Leica DM 2500). Back-
ground correction and adjustment of brightness and
contrast were performed using Leica confocal software.
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were sequentially acquired and average projected.
For immunofluorescence quantification the cellSens
DimensionDesktop Version 1.4.1 XV 3.4 (Build 8624)
software from Olympus was used. The green fluores-
cence (green for PRG3) intensity was measured in a
region of interest (ROI, 4–5 μm2) as a maximum pixel
fluorescence intensity drawn over three distinct MAP2
positive or tau1 positive areas for the PRG3 abun-
dance on tau1 and MAP2 positive structures. All mea-
surements were performed using three different
immunostainings. Data analysis was performed using
GraphPrism 4 (GraphPad Software Inc, La Jolla, CA,
USA) from n = 105 ROIs for MAP2 and n = 111 ROIs
for tau1 positive structures. Data are reported as
mean +/− SEM.
The red fluorescence (red for endogenous PRG3) in-
tensity was measured in a region of interest as a mean
pixel fluorescence intensity drawn over five distinct
areas, to quantify the knock-down (PRG3 shRNA versus
control shRNA) efficiency in Tuj1 positive neurons. All
measurements were performed using three different
immunostainings. Data analysis was performed using
GraphPrism 4 (GraphPad Software Inc, La Jolla, CA,
USA) from n = 28 for PRG3 shRNA and n = 30 for con-
trol shRNA transfected neurons. Data are reported as
mean +/− SEM.RNA extraction and cDNA synthesis
Organs were harvested from C57BL/6 mice and ho-
mogenized in TRIzol (Invitrogen) reagent. Primary neu-
rons, microglial cells, or astrocytes were scraped in
PBS, centrifuged for 5 minutes at 900 rpm and 4°C. Cell
pellets were dissolved in TRIzol reagent. Total RNA
was extracted using TRIzol reagent according to the
manufacturer’s protocol. The concentration and purity
of the isolated total RNA were determined by spectro-
photometric analysis (Biomate 3 spectrometer, Fisher
Scientific, Schwerte, Germany). cDNA was synthesized
with 5 μg of total RNA using the High-Capacity cDNA
Archive Kit (Applied Biosystems, Carlsbad, CA, USA)
according to the manufacturer's protocol. As a control,
reaction was performed without MultiScribe reverse
transcriptase. cDNA was diluted 1:5 with RNase,
DNase-free water and stored at −20°C. The quality of
the amplified cDNA (with and without MultiScribe re-
verse transcriptase) was controlled by β-actin PCR.
Identity and purity of primary cells was shown by quan-
titative real-time PCR with the neuron-specific class III
β-tubulin (tuj1) as a marker for neurons, the glial fibril-
lary acidic protein (GFAP) as a marker for astrocytes
and the ionized calcium-binding adaptor molecule 1
(Iba1) as a marker for microglial cells [22].Quantitative real-time PCR
Reverse transcriptase real-time quantitative polymerase
chain reaction (qRT-PCR) was performed with the follow-
ing gene expression assays: PRG3 (Mm00626670_m1),
Iba1 (Mm00479862_g1), GFAP (Mm00546086_m1), tuj1
(Mm00727586_s1), GAPDH (Assay ID 4352932E) and β-
actin (Assay ID 4352933E) (Applied Biosystems). For
HPRT, separate primer and probe were used (Primer Mix:
for 5´-ATCATTATGCCGAGGATTTGGAA-3´; rev 5´-
TTGAGCACACAGAGGGCCA-3´ and probe 5´-TGGA
CAGGACTGAAAGACTTGCTCGAGATG-3´). The PCR
was run on the ABI PRISM™ 7700 Sequence Detection
System (Applied Biosystems) and the data obtained were
processed by ABI PRISM software. Standard curves were
produced with serial dilutions of cDNA from P10 mouse
cortex with amplification efficiency between 90 and 100%.
Data were normalized to two different house-keeping
genes (β-actin and HPRT), which produced similar results.
Each result is the average of three separate experiments
and error bars represent SD.
Morphological analysis
Primary neurons were transfected after 1 day in vitro
(DIV 1) with the shPRG3 construct, the shPRG3 con-
struct together with a PRG3 rescue mutant, or control
shRNA targeting firefly luciferase using Effectene and
analysed at DIV 4. For the morphological analysis fluor-
escence images were acquired with an Olympus BX50
microscope equipped with Metamorph software (ver-
sion: 6.2r4, Molecular Devices Inc, Sunnyvale, CA,
USA). Confocal images of primary neurons were ac-
quired with an upright laser microscope (Leica DM
2500) equipped with a 63× objective (oil-immersion,
1.2 NA) using the 488 nm line of an argon-ion laser.
Background correction and adjustment of brightness
and contrast were performed using Leica confocal soft-
ware (Leica Microsystems, Germany). The length of the
longest neurite was measured in Metamorph. For sub-
sequent analyses the numbers of branching points were
determined by counting the number of neurites
according to their respective order (ImgaeJ 1.43u, Java
1.6.0_10 32-bit). A neurite was classified as a “branch”
when it was longer than 10 μm. The number of protru-
sions between 2 and 5 μm and between 5–10 μm were
quantified as separate subgroups. For both groups pro-
trusion length was measured from the tip to the inter-
section with the protrusion shaft. The mean total
process length per neuron was evaluated by quantifying
the length of all processes (ImageJ 1.45s, Java 1.6.0_35
64-bit). For averaging the protrusion length per neuron
the major neurite was omitted. All measurements were
performed using three to four different transfection
preparations by investigators blind to the experimen-
tal conditions. Data analysis was performed using
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which are also presented as error bars in the figures.
Significance was assessed using the two-tailed student's
t-test for unpaired data at the given significance level
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and filopodia were not visible. (D) Co-localization images show wild-type P
mutated PRG3 shows no co-localization. Scale bar: 5 μm.Results
PRG3 Requires N-glycosylation for insertion in the cell
membrane and influencing of filopodia development
In order to identify the prerequisites for PRG3 ac-
tivity, e.g. intracellular as opposed to plasma-membrane3Q










embrane insertion and filopodia formation. (A) Western blot of
ith N-glycosidase F. When treated with N-glycosidase F a band is
ing to an N-glycosylation of PRG3. (B) Western blot of HEK293 cells
FLAG-rPRG3 N163Q). Native lysates (lanes 1 and 3) or lysates treated
dy. Mutation of asparagine 163 to glutamine (lanes 1 and 2) almost
still N-glycosylated (lanes 3 and 4). (C) Confocal images of
xFLAG-rPRG3 N163Q (middle) in comparison to control-transfected cell
struct show no increase of filopodia formation, which are prominently
ed with a primary anti-FLAG and a secondary alexa488 antibody. Scale
ation displayed in the left lower left corner. Cells were visualized with
93 cells expressing 3xFLAG-rPRG3 exhibited filopodia and rPRG3 was
ty vector control showed no localization in the plasma membrane
RG3 co-localized with the surface marker Na+/K+-ATPase, whereas
Velmans et al. BMC Neuroscience 2013, 14:36 Page 8 of 19
http://www.biomedcentral.com/1471-2202/14/36binding, we raised two polyclonal antibodies against
PRG3. One was targeted at an extracellular loop (anti-
PRG3 53) and the other at the intracellular C-terminus
(anti-PRG3 296) (Figure 1A). Both new antibodies were
shown to be sensitive as they detected the PRG3 protein i.)
when endogenously present in mouse brain protein lysates,
and ii.) when fused to GFP (GFP-rPRG3) and over-
expressed in HEK293 cells (Figure 1B,C). Specifically,
Western blot analysis showed one double band at 37–40
kDa in native brain lysates and another double band at
61–64 kDa in PRG3-overexpressing HEK293 cells
(Figure 1B,C). The bands match the in silico predicted mo-
lecular weight of 36 kDa for PRG3 and 63 kDa for the
GFP-tagged PRG3 (ExPASy, http://www.expasy.ch/tools).
Both antibodies are specific, as PRG3 was undetectable
after pre-incubation of the antibodies with their corre-
sponding peptides (Figure 1B,C). Further, we detected no
cross-reaction to other PRG family members with both
antibodies (Figure 1D).
The existence of double bands in the immunoblots
points to a putative glycosylation of the PRG3 protein.
Indeed, hydrolyzation of N-linked glycan chains from
mouse brain glycoprotein lysates with peptide-N-glycosi-
dase F (PNGase F) [23] resulted in a single band with
lower molecular weight (approximately 32 kDa) in the
immunoblot using anti-PRG3 53 (Figure 2A). Further-
more, we identified a putative consensus N-glycosylation
site at aa 163 within the second extracellular loop via
in silico analysis of rat and mouse PRG3 (Figure 1A,
marked in red; revealed by using NetNGlyc 1.0, http://
www.cbs.dtu.dk/services/). Glycosylation is a posttrans-
lational modification that plays a crucial role in the
sorting and targeting of numerous proteins to their re-
spective cell compartments [24]. We therefore hypothe-
zised that altered PRG3 glycosylation could strongly
influence its subcellular localization. To abolish N-
glycosylation we point-mutated PRG3 (N163Q) by sub-
stituting asparagine for glutamine [25]. This N163Q
mutation in its native, non-deglycosylated form showed
only the lower molecular weight band of the endogenous
protein together with a second band on the molecular
weight of the deglycosylated form compared to wild-type
3xFLAG-PRG3 (Figure 2B). With PNGase F treatment
the N163Q mutant showed a single band at approxi-
mately 32 kDa.
Next, we tested whether the N-glycosylation of PRG3
influences plasma membrane targeting by transfecting
wild-type 3xFLAG-PRG3 and 3xFLAG-PRG3 N163Q
into HEK293 cells. Overexpression of 3xFLAG-PRG3
induceed an increase in filopodia formation in comparison
to control-transfected cells (empty vector), whereas the
3xFLAG-PRG3 N163Q mutant showed no alteration in
the morphology compared to controls (Figure 2C). Add-
itional evidence for membrane localization was obtainedby staining with the surface marker Na+/K+-ATPase [26].
Mutated PRG3 failed to localize into the plasma membrane,
in contrast to wild-type PRG3 that showed co-localization
with the plasma membrane marker (Figure 2D).
Taken together, both endogenous PRG3 and 3xFLAG-
PRG3 fusion proteins were glycosylated by N-glycosylation,
which is required for the plasma membrane targeting of
PRG3. PRG3 overexpression induces filopodia formations.
However, the lack of PRG3 in the plasma membrane did
not alter the cell morphology.
PRG3 is mainly expressed in the brain and is
developmentally regulated
As the formation of processes is a prerequisite for the
development of most tissues, we comparatively analyzed
mouse PRG3 mRNA expression in different organs at P5
by quantitative RT-PCR (Figure 3A). This revealed the
highest levels of PRG3 expression in brain and at least
ten times lower levels in kidney, liver and testis. Add-
itionally, lung tissue showed only a very weak signal that
was just above the detection level. No PRG3 mRNA ex-
pression was detectable in thymus and spleen (Figure 3A).
Interestingly, Western blot analysis only showed PRG3
protein expression in brain protein lysates (Figure 3B).
There was no signal for any of the mouse tissues even after
prolonged chemiluminescence exposure. The anti-PRG3
296 antibody yielded the same result (data not shown).
Given that PRG3 mRNA has been shown to be devel-
opmentally regulated in the hippocampal region [18], we
evaluated the abundance of PRG3 mRNA and protein
expression during development in this area. Between
E16 and P5 we detected PRG3 mRNA at high levels in
hippocampal tissue (Figure 3C). PRG3 mRNA expression
then decreased more than 10-fold between P5 and P30
(Figure 3C). This expression pattern was reflected on the
protein level: the level of PRG3 protein expression was
high between E16 and P20, peaked between P5 and P10
and rapidly decreased until adulthood (Figure 3D). These
data suggest that the PRG3 protein is exclusively expressed
in brain tissue and that PRG3 might contribute to hippo-
campus development.
PRG3 is prominently expressed in neurons
To further specify the cellular abundance of PRG3 we
used qRT-PCR to analyze its expression in primary cul-
tured neurons, astrocytes and microglial cells. Primary
cultured hippocampal neurons showed the highest levels
of PRG3 mRNA, whereas the signal was over ten times
weaker in astrocytes and microglial cells (Figure 4A). In
Western blot analysis PRG3 expression was clearly de-
tectable in primary neurons, whereas we found no PRG3
signal in cultured astrocytes and microglia (Figure 4B).
The purity of primary cells was tested by immunoblot-


































   






















































   



























Figure 3 PRG3 is mainly expressed in the brain and expression decreases during maturation. (A) Quantitative real-time PCR of different
mouse tissues (age P5) revealed the most prominent PRG3 mRNA expression in the brain. Data were normalized to β-actin. (B) Western blot
analysis of protein lysates from various mouse tissues (age P5) shows a solitary signal in brain lysates (probed with anti-PRG3 53 antibody). No
protein was detected in lysates from other tissues (top). As loading control β-actin was used (bottom). (C) Quantitative real-time PCR of mouse
hippocampal tissue between E16 and P30 revealed age-dependent changes in expression levels. The highest PRG3 mRNA expression was
detected around birth with a decline in expression levels until adulthood. Data were normalized to HPRT. (D) Western blot from total protein
lysates of mouse hippocampal tissue between E16 and P60 (anti-PRG3 53 antibody). A signal was detected from E16 onwards with the strongest
signal found around P5. From P10 to P20 a decrease in signal intensity appeared and after P20 the signal was hardly detectable (top). Anti-β
-actin was used as loading control (bottom).
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PRG3 had no influence on intrinsic and general bio-
physical neuronal properties. We determined this by
establishing different PRG3 levels in neurons via over-
expression of PRG3 or shRNA-induced reduction of
native PRG3 and compared the functional properties to
the corresponding controls. To determine the PRG3
shRNA efficiency we analysed western blots after over-
expression of PRG3 together with the shRNA in
HEK293 cells. As specificity control of the PRG3 shRNA
we generated a PRG3 shRNA-resistant construct, which
was not effected by the PRG3 shRNA (Figure 4C). Fur-
thermore, to demonstrate the neuronal specificity of the
PRG3 shRNA we analysed and quantified the endogen-
ous PRG3 level in primary neurons after transfection of
the shRNA by immuncytochemistry (Figure 4D). The
endogenous PRG3 level, detected by antibody staining,was reduced to less than 50% after transfection with the
PRG3 shRNA. In both approaches we detected a clear
reduction of PRG3 protein.
The neurons responded consistently to a family of
hyper- and depolarizing currents (Figure 4E). In particu-
lar, suprathreshold currents evoked repetitive action po-
tentials in all neurons. Subthreshold current injections
were used to determine additional parameters of intrin-
sic neuronal excitability such as input resistance and
resting membrane potential. Irrespective of the cellular
amount of PRG3 these parameters appeared similar.
Moreover, the whole cell capacity, an approximated
measurement of the cell surface, did not differ between
the experimental groups (Figure 4F). Hence, PRG3 is
predominantly expressed in primary cultured hippocam-
pal neurons, but does not profoundly interfere with the
basal intrinsic functional properties of these neurons.
Figure 4 PRG3 is neuron specific. (A) qRT-PCR analysis revealed a ten times stronger PRG3 mRNA expression in neurons compared to astrocytes
and microglia. Data were normalized to GAPDH. (B) WB from total protein lysates of primary brain cells. PRG3 protein was only detected in
neurons. The membrane was reprobed with anti-tuj1, anti-GFAP, and anti-Iba1 to verify the quality of the lysates (right). Anti-β-actin was used as
loading control. (C) Verification of the PRG3 shRNA and the shRNA resistant PRG3 construct by WB. GFP-mPRG3 was reduced when compared to
control or to the PRG3 shRNA-resistant protein levels. Ratios below the WB bands refer to densitometric measurements of the gray intensity of
these bands in relation to the control band. Anti-β-actin was used as loading control and for normalization. (D) Quantification of the efficiency of
PRG3 shRNA. PRG3 shRNA (n = 28) expression reduced the endogenous PRG3 expression to more than 50% when compared to controls (n = 30).
(E) Recordings of membrane voltage in response to a family of 1 second long square current pulses (see inset) from neurons expressing GFP
(upper left), GFP-mPRG3 (lower left), control vector (upper right), or PRG3 shRNA (lower right). Irrespective of the PRG3 protein level, voltage
responses including repetitive action potentials were roughly similar among all neurons. (F) Population data of intrinsic neuronal characteristics
are displayed for the four groups of neurons depicted in D. Individual values for each neuron are shown at the right of each box plot. No
differences in the resting membrane potential, input resistance, or capacity were found between GFP (n = 12), GFP-mPRG3 (n = 13), shRNA
control (n = 4) or PRG3 shRNA-expressing cells (n = 6). An ANOVA resulted in p values of p = 0.07 (resting membrane potential), p = 0.15 (input
resistance), and p = 0.51 (capacity).
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http://www.biomedcentral.com/1471-2202/14/36Subcellular distribution of endogenous PRG3 in primary
hippocampal neurons changes during development
Motivated by the prominent neuronal expression of en-
dogenous PRG3 and its role in filopodia formation, we
investigated the subcellular distribution of PRG3 in pri-
mary neurons at different developmental stages. After 1
day in culture, hippocampal neurons exhibited several un-
differentiated, α-tubulin-containing processes of similar
length (Figure 5A). During this initial phase of neuronal
development, PRG3 appeared as a dotted, clear, strong
signal in the plasma membrane and as weaker intracellular
signal (Figure 5A and 5B). Beta-actin was strongly local-
ized in growth cones and lamellipodia. Interestingly,
PRG3 was expressed all over the plasma membrane except
in the growth cones and lamellipodia, where ß-actin was
located (Figure 5B). The distribution of PRG3 was uni-
form in more mature polarized neurons (DIV 4, Figure 6).
Here, the microtubule cytoskeleton turns into parallel ori-
ented bundles to form a nascent neurite shaft (Figure 6A)
tipped by an actin-rich growth cone (Figure 6B). PRG3
was expressed in the plasma membrane along the neurite
shafts, whereas β-actin-rich areas of the growth cone
lacked PRG3 expression (Figure 6B). At this developmen-
tal stage, the neurons had established a single axon and
several dendrites. PRG3 was present in the neurite shafts
of axons, as shown by co-localization with tau1, an axonal
marker protein, (Figure 6C) as well as in dendrites, as
shown by co-localization with MAP2, a dendritic marker
protein (Figure 6D).
However, in neurons at DIV 14, when an extensive net-
work of synaptic connections is established, PRG3 was pre-
dominantly expressed in axons (Figure 7A) as shown by
co-localization with tau1. In contrast, neurites that were
positive for MAP2 (Figure 7B) showed hardly any PRG3
expression at this time point. To measure the abundance
of PRG3 in axons and dendrites, the fluorescence intensity
of PRG3 on tau1 or MAP2 positive structures were ana-
lyzed. The PRG3 expression on MAP2 positive structures
is only half the amount as on tau1 positive structures
(Figure 7C). In summary, PRG3 was present in all neurites
after the beginning of axogenesis at DIV 4, but shifted to-
wards predominant axonal expression by DIV 14.
PRG3 Knock-down in young primary hippocampal
neurons decreases the number of neurites
Because filopodia formation is a crucial step in neurite
outgrowth, PRG3 might influence cell morphology. To
investigate the effect of endogenous PRG3, primary neu-
rons were transfected with PRG3 shRNA and morpho-
logically analyzed. We neither observed a difference in
the number of branching points (Figure 8A, Table 1) nor
in the length of the longest neurite (Figure 8B, Table 1).
However, shRNA-induced knock-down of PRG3 expres-
sion decreased the number of neurites with a lengthbetween 2 and 5 μm (t-test, p = 0.0018, Figure 8C,D,
Table 1), whereas neurites with a length between 5–10
μm were not changed in number. Additionally, the
average neurite length per neuron showed no alteration
between PRG3 knock-down and control (Figure 8E,
Table 1). To confirm that the observed neuronal pheno-
type was a specific result of the PRG3 shRNA expres-
sion, the PRG3 shRNA knock-down neurons were
co-transfected with an shRNA-insensitive PRG3 con-
struct. The numbers of neurites with a length of 2–5 μm
in neurons co-expressing PRG3 shRNA and shRNA-
resistant PRG3 was not different from that in those
expressing control shRNA. Thus, overexpression of
shRNA-resistant PRG3 in PRG3 knock-down neurons
completely rescued the reduction of neurites with a
length of 2-5μm (Figure 8D,E, Table 1).
We also performed opposite analyses by overexpressing
PRG3 in young (DIV 4) primary neurons. Here, we demon-
strated an increase in the number of neurites with a length
between 2–5 μm, but no change in number of neurites with
the length of 5–10 μm (t-test, p = 0.0489, Figure 8F, G,
Table 1). However, the average neurite length per neuron
was not affected by PRG3 overexpression (Figure 8H,
Table 1). This set of data suggests that PRG3 is involved in
the induction of protrusions at the neurite shaft.
PRG3 Distribution is not influenced by and does not
affect synaptic currents in cultured Hippocampal neurons
The PRG3 shift occurred in time and space in parallel to
the beginning synaptogenesis of hippocampal neurons in
culture [27]. We thus hypothesized first that the den-
dritic attenuation of PRG3 might ease stabilize synapse
formation or second that developing synaptic inputs
contribute to the PRG3 shift. An overexpression system
was particularly suitable for investigating the first hy-
pothesis because differences in expression levels between
axon and dendritic structures seen in endogenous PRG3
protein distribution (Figure 7A,B) were not detectable
(Figure 9A). We selected DIV10 as time point of transfec-
tion, because the PRG3 shift reached a steady state and
synaptogenesis was still on a low level before the steep in-
crease from DIV 14 on [27]. At DIV 12 we somatically
recorded miniature excitatory synaptic currents (mEPSCs)
of PRG3-overexpressing neurons (exemplified in Figure 9B)
and respective controls. The mEPSCs were pharmacologic-
ally and electrically isolated. This was achieved in the pres-
ence of 0.5 μM tetrodotoxin, 10 μM bicuculline and a
holding potential of −70 mV (Figure 9B). In the case a den-
dritic persistence of PRG3 interfered with proper synapse
formation, we expected differences in incoming signals.
However, neither the frequency nor the mean amplitude of
the mEPSCs was affected by elevated levels of PRG3 dis-
tributed throughout the cell when compared to neurons







Figure 5 Endogenously expressed PRG3 is found in the plasma membrane of primary hippocampal neurons after DIV 1. (A) Confocal
images of a representative primary hippocampal neuron fixed after DIV 1. Low (top row) and high (bottom row) magnification of this neuron
showed that PRG3 (anti-PRG3 296, green) is not co-localized with α-tubulin (anti-α-tubulin, red) and is likely located in the plasma membrane. (B)
Confocal images of a primary hippocampal neuron stained with anti-PRG3 296 (green) and anti-β-actin (red) after DIV 1. As in (A), PRG3 is located
in the plasma membrane, but is only present in actin-rich regions and growth cones at low levels. Overview (top row), scale bar: 10 μm, higher
magnification (bottom row), scale bar: 5 μm.
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that synaptic inputs might have affected the PRG3
dendrite-axonal shift, we blocked all inputs to the
postsynaptic dendrites by supplementing the media
with 20 μM CNQX to block AMPA/kainate receptors,
100 μM DAPV to block NMDA receptors, and 4 μMgabazine to block GABAA receptors. Such treatment
from DIV 4 to DIV 14 did not lead to any change in
the PRG3 dendrite-axonal shift (Figure 9D). We ob-
served a gradual localization shift of PRG3 from den-
drites to axons over several days (Figure 9D). Both















Figure 6 Endogenous PRG3 is located in neurites and growth cones of primary hippocampal neurons after DIV 4. (A) Confocal images
of a typical extension of a hippocampal neuron at DIV 4, stained with anti-PRG3 296 (green, left) and anti-α-tubulin (red, middle). An overlay
(right) shows that native PRG3 is found in all neurites, regardless of their fate. (B) Confocal images of a representative hippocampal neuron
stained with anti-PRG3 296 (green) and anti-β-actin (red) showing that PRG3 is present in high amounts at the onset of the neurite, but only in a
very small amount at the growth cone, which stained strongly for β-actin. (C) Confocal images of a hippocampal neuron stained with anti-PRG3
296 and anti-tau1 antibodies, and (D) a neuron stained with anti-PRG3 296 and anti-MAP2 show similar distribution of PRG3 at the neurite shaft,
irrespective of the underlying structure. Scale bars: 10 μm.







































Figure 7 After DIV 14 PRG3 is mainly found in axons of primary hippocampal neurons. (A) Confocal images of axonal structures from
hippocampal neurons stained with anti-PRG3 296 (green) and anti-tau1 (red) reveal that PRG3 is co-localized with these structures. (B) Confocal
images of dendritic extensions stained with anti-PRG3 296 (green) and anti-MAP2 (red) show that PRG3 is not localized in dendrites. Scale bar: 10
μm, also applies to A. (C) Analyses of the PRG3 abundance on tau1 and MAP2 positive structures measured as the fluorescence intensity signal.
The fluorescence intensity of PRG3 in tau1 positive structures (n = 111) is significantly higher compared to the PRG3 fluorescence intensity in
MAP2 positive structures (n = 105) (p < 0.0001).
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ring synaptic events.
Discussion
We present novel findings regarding the role of PRG3
during neuronal development. Firstly, we provide evi-
dence that posttranslational modification of PRG3 is es-
sential for plasma membrane targeting and that neurite
outgrowth is affected by mislocated PRG3. Secondly, we
demonstrate dominant PRG3 mRNA and protein ex-
pression and localization in primary neurons that was
dynamically regulated during development. Thirdly,
functional analysis has revealed that PRG3 is involved in
the induction of protrusions at the neurite shaft.
Posttranslational modification of PRG3
PRG3 appeared as a glycoprotein after transfection in
HEK293 cells and endogenously in mouse brain lysates.
PRG3 is N-glycosylated, as predicted by in silico analysis
and previously reported by others [20]. The N-glycosylation
sequence in the second extracellular loop of PRG3 has also
been identified in other LPT family members as a consen-
sus glycosylation sequence [25,28]. In addition, our results
show that N-glycosylation of PRG3 is essential for plasma
membrane localization and that the latter is required for an
increase of filopodia formation. However, PRG3 is also lo-
calized at intracellular membrane structures [18,20], seem-
ingly independently of N-glycosylation.
Endogenous PRG3 expression during development
Previous studies have shown the distribution of PRG3
transcripts in rat and mouse brains [18,19]. Furthermore,semiquantitative Northern blot analysis revealed highest
mRNA expression in brain and lower levels in liver, kid-
ney and testis [18]. These data are in line with our re-
sults, which showed approximately 10-fold higher
mRNA expression levels in brain compared to liver, kid-
ney and testis. On the protein level, PRG3 only appeared
in brain samples. Therefore, we conclude that the ex-
pression level in kidney, liver and testis is below the de-
tection level of our newly generated antibodies. In
contrast, an antibody directed against a sequence located
on the C-terminus of PRG3 just before the sequence
used for generating anti-PRG3 296 in this study, re-
vealed a strong PRG3 expression signal in kidney, lung,
and spleen, whereas a weaker signal appeared in brain
and heart tissue and hardly any signal was observed in
liver [20]. However, similar to the antibodies generated by
us, the latter antibody also detected PRG3 overexpression
and endogenous PRG3 expression as a double band
around the predicted molecular mass [20]. As we could
not detect any mRNA expression in spleen tissue, the dif-
ferences between these antibodies in detecting PRG3 pro-
tein expression levels cannot simply be explained by
distinctions in the respective detection sensitivities of the
antibodies. Further investigations are required to clarify
this discrepancy.
Functional role of PRG3
PRG3 expression is dynamically regulated after birth.
We show that PRG3 mRNA levels and PRG3 protein
levels decreased around ten-fold between P0 and P30. In
contrast to the early embryonic expression of PRG3,





































































































































































Figure 8 PRG3 knock-down reduces the formation of small neurites. (A) Primary neurons were transfected with PRG3 shRNA or control
shRNA at DIV 1 and morphologically analyzed at DIV 4. Determination of branching points according to branching order revealed no differences
between the two groups (n = 80). (B) Axon length measurement, in which the longest neurite of the transfected neuron was measured (n = 32).
(C) Confocal images of representative transfected primary neurons showed a decreased quantity of small neurites in PRG3 shRNA-expressing
neurons compared to controls. Scale bar: 5 μm. (D) All neurites within one neuron were grouped between lengths of 2–5 μm and 5–10 μm and
are presented as subgroups. PRG3 knock-down decreased the number of neurites between 2–5 μm (p = 0.0006) but not in the number of
neurites with a length between 5–10 μm. We co-transfected primary neurons with a PRG3 rescue plasmid together with the PRG3 shRNA. The
double transfected neurons show neither a reduction of neurites with a length between 2–5 μm nor neurites with a length between 5–10 μm.
(E) PRG3 knock-down did not affect the average neurite length per neuron as revealed by comparing PRG3 shRNA expression neurons to
controls or to the PRG3 shRNA resistant construct. (F) Confocal images of representative transfected primary neurons showed an increased
quantity of small neurites in PRG3-eGFP-expressing neurons compared to controls. Scale bar: 5 μm. (G) PRG3 overexpression leads to an increase
in the number of neuritis with a length between 2–5 μm (p <= 0.0489). No effect was detectable in the number of neuritis with a length
between 5–10 μm. (H) The average neurite length for each neuron was unchanged for PRG3-eGFP overexpressing cells and respective controls.
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Table 1 Data of Figures 8A, B, D, E, G, and H
8A shRNA control (n=80) PRG3 shRNA (n=82)
Mean SEM Mean SEM
1st order 4.138 0.1666 4.012 0.1799
2nd order 3.900 0.2154 3.890 0.2733
3rd order 2.113 0.1949 2.390 0.2214
4th order 0.9625 0.1394 1.085 0.1648
5th order 0.4250 0.1163 0.6463 0.1359
8B shRNA control (n=32) PRG3 shRNA (n=32)
Mean (μm) SEM (μm) Mean (μm) SEM (μm)
Major neurite 210.50 17.86 202.20 14.75
8D shRNA control PRG3 shRNA PRG3 rescue mutant
Mean SEM Mean SEM Mean SEM
Neurites 2–5 μm 8.551 (n=89) 0.645 5.862 (n=94) 0.426 9.938 (n=16) 0.9978
Neurites 5-10μm 3.612 (n=67) 0.338 2.806 (n=72) 0.2387 3.875 (n=16) 0.5764
8E shRNA control PRG3 shRNA PRG3 rescue mutant
Mean SEM Mean SEM Mean SEM
neurite length 51.71 (n=60) 2.647 56.29 (n=61) 3.845 59.28 (n=16) 7.253
8G eGFP control PRG3-eGFP
Mean SEM Mean SEM
Neurites 2–5 μm 9.345 (n=58) 01.005 12.90 (n=58) 1.474
Neurites 5-10μm 4.776 (n=58) 0.3997 5.103 (n=58) 0.4179
8H eGFP control PRG3-eGFP
Mean SEM Mean SEM
neurite length 56.88 (n=60) 4.497 57.59 (n=60) 3.389
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birth in the hippocampus and entorhinal cortex [17].
This temporal expression pattern during brain develop-
ment suggests either different or complementary func-
tional roles of both proteins. Our data rather point to
the first option. PRG1 function has been suggested as an
important player in the control of hippocampal excit-
ability [29] and it promotes outgrowth capability during
regenerative sprouting [17]. However, PRG3 is expressed
along all neurites in young cultured hippocampal neu-
rons, with higher expression in the neurite shafts than in
ß-actin-positive growth cones. Both a highly dynamic
growth cone and a stable neurite shaft are required for
neurite extensions. The neurite shaft is generated during
the consolidation process, which results from the col-
lapse of the proximal part of the growth cone and the
suppression of protrusive activity along the neurite [2,8].
In addition to the localization of PRG3, our molecular
data (knock-down and overexpression) lead us to pro-
pose that PRG3 has a function in the control of neurite
shaft protrusion. Neurite consolidation requires constant
active repression of protrusive activity [10]. We demon-
strate that knock-down of PRG3 reduces the capacity ofyoung hippocampal neurons to initiate protrusions. This,
together with results of previous studies showing that
PRG3 overexpression in different cells induces filopodia
formation [18,20], suggests that PRG3 plays a role in the
regulation of neurite shaft consolidation and could
therefore control filopodia formation. Thus, PRG3 could
act as a mediator for extracellular cues, which influence
the initiation of neurites at the neurite shaft [30,31],
therewith controlling active neurite consolidation.
Interestingly, PRG5, another member of the PRG fam-
ily, induces cdc42-independent filopodia formation [32].
Whether both of these proteins act together in the
process of neurite outgrowth will be clarified in the
future.
In the more mature developmental stage of primary neu-
rons, endogenous PRG3 expression switches to a mainly
axon-specific expression pattern. Generally, neurites ac-
quire either axonal or dendritic identity during develop-
ment. In this process, some growth-promoting molecules
like PAR1, PAR6 and phospho-GSK-3β, which had initially
been expressed in all neurites, are restricted solely to one
neurite, which subsequently becomes the axon [33]. Both
the establishment and maintenance of neuronal polarity
DIV 6
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Figure 9 Synaptic activity is neither altered by different dendritic PRG3 levels nor changes in PRG3 distribution. (A) Image of a
representative hippocampal neuron shows an evenly distributed PRG3 signal (anti-GFP) when overexpressed. Scale bar: 75 μm. (B) Representative
current recordings from cultured hippocampal neurons either overexpressing GFP (native PRG3 level; control) or overexpressing a GFP-mPRG3
construct. mEPSCs were pharmacologically isolated (see Methods) and recorded at −70 mV. (C) Box plots of mEPSC frequency and mean
amplitude box plots, as well as distribution of individual values. (Left) mEPSC frequency measured for each neuron is summarized and displayed
as a statistical plot. Individual values are shown to the right of each box. No difference was observed (Mann–Whitney U test, p = 0.16, n = 12).
(Right) For each neuron all mEPSC amplitudes were averaged. The mean amplitudes for each neuron are shown for either GFP (control) or GFP-
mPRG3-overexpressing neurons. No difference was observed, regardless of the PRG3 level (unpaired t-test, p = 0.27, n = 12). (D) Immunocytochemistry
analyses of PRG3 expression distribution on tau1 and MAP-2 positive structure with and without activity blockers. This treatment from DIV 4 to DIV 14
in culture did not change in the shift of PRG3 from dendrites to axons. Scale bar: 5 μm.
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cytoskeleton and membrane-trafficking machinery [33].
Whether PRG3 plays a role in this context remains to be
examined in further studies.
Furthermore, overexpression or knock-down of PRG3
in juvenile primary hippocampal neurons induced no
changes in membrane resistance or potential. This sug-
gests that PRG3 expression and localization do not
interfere with basic intrinsic neuronal properties and
functions at this time point. Although their temporal
and spatial similarity is striking, there appeared to be no
functional coupling between dendrite-axonal shift of
PRG3 and synaptic function. Our present approach
targeted the capacity of neurons with pre-existing synap-
ses to regulate the amount of new synapses or its function
by dendritic PRG3 levels. At the time chosen, continuous
synaptogenesis occurs with approximately 1 synapse per
hour [34] with rather an upward trend [27]. However, the
ability of synapses to form (initial de novo synaptogenesis)
seems independent of PRG3, because spontaneous excita-
tory postsynaptic potentials were detected in cultured hip-
pocampal neurons already at DIV 4 [35], a time point
when dendrites are still packed with PRG3.
The lack of an influence on synaptic function in juven-
ile hippocampal neurons distinguishes PRG3 from its
family member PRG1, which has been shown to influ-
ence mEPSC frequencies in the CA1 of juvenile mice
[29]. Interestingly, PRG1 has also been shown to be lo-
cated mainly in dendrites under non-pathological condi-
tions. However, PRG1 protein expression was specifically
upregulated in regrowing axons in the denervated outer
molecular layer following lesion of the entorhinal cortex.
There it attenuates phospholipid-induced axon collapse
in neurons and facilitates outgrowth in the deafferented
zone [17]. It remains to be elucidated whether PRG3
also plays a role in neuronal regeneration processes.
Conclusion
In conclusion, PRG3 is highly expressed and regulated
during brain development. It exhibits a mainly neuron-
specific expression pattern. PRG3 is strongly expressed
in the neurite shaft in young primary neurons. The
knock-down of PRG3 reduces the capacity of young hip-
pocampal neurons to initiate protrusions along the
neurite shaft. Therefore, PRG3 could play a role in the
regulation of active neurite consolidation. In more mature
neurons, PRG3 expression is predominantly localized in
the axon, and changes in PRG3 expression distribution do
not affect currents.
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